---
document_datetime: 2026-01-07 13:32:48
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lenalidomide-krka-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lenalidomide-krka-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1778699
conversion_datetime: 2026-01-10 11:42:06.893858
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lenalidomide Krka

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|----------------------|-------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Renewal - 5 year /   | - Renewal - | 16/10/2025                          | 04/12/2025                                  | SmPC and PL                      | Based on the review of data on quality, safety and |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/R/0000272358   | Renewal of marketing authorisation.   | efficacy, the CHMP considered that the benefit-risk balance of Lenalidomide Krka in the approved   |
|--------------------|---------------------------------------|----------------------------------------------------------------------------------------------------|